Correlation of Inflammatory Markers,Survival,and COX2 Expression in Oral Cancer and Implications for Prognosis

Abstract

Objective

Peripheral blood–derived inflammation-based scores, such as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and the combination of platelet count and NLR, have recently been proposed as prognostic markers in solid tumors. The purpose of this study was to investigate the validity of inflammatory markers as predictive prognostic factors for locally advanced oral squamous cell carcinoma (OSCC). In addition, we evaluated the potential correlation between systemic inflammation and local expression of COX2.

Study Design

Retrospective chart review and histologic analysis.

Setting

Tertiary referral academic center.

Subjects and Methods

We conducted a retrospective analysis of 94 patients with advanced OSCC treated with surgery at our hospital between 2007 and 2015. The relationship among patient survival, systemic inflammatory markers, and local COX2 expression was evaluated. Local COX2 expression in surgical specimens was measured by immunohistochemistry.

Results

High NLR and high PLR were associated with significantly shorter overall survival and cancer-specific survival. Multivariate analysis revealed that cN stage, NLR, and postoperative radiation/chemoradiation were significantly associated with overall survival and cancer-specific survival. PLR and combination of platelet count and NLR were significantly correlated with tumor expression of COX2. Finally, patients with cN2 stage disease and high local COX2 expression had a significantly worse prognosis than other patient groups.

Conclusion

Pretreatment inflammatory markers are useful as prognostic factors in advanced OSCC. Our study suggests that local COX2 may be affected by systemic inflammation and that the prognostic impact of COX2 expression depends on host factors and tumor characteristics.

Keywords

prognosis oral squamous cell carcinoma inflammation neutrophil-lymphocyte ratio platelet-lymphocyte ratio COX2

Get full access to this article

View all access options for this article.

References

Grobe

Blessmann

Hanken

et al . Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity. Clin Cancer Res. 2014;20:425-433.

Gupta

Kong

Peng

Miao

Mackillop

WJ.

Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. Int J Cancer. 2009;125:2159-2165.

Ferris

Blumenschein

Jr. Fayette

et al . Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-1867.

Koh

Bhoo-Pathy

et al . Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113:150-158.

Kogashiwa

Yasuda

Sakurai

et al . PD-L1 expression confers better prognosis in locally advanced oral squamous cell carcinoma. Anticancer Res . 2017;37:1417-1424.

Clarke

Chua

Moore

et al . Use of inflammatory markers to guide cancer treatment. Clin Pharmacol Ther. 2011;90:475-478.

Zhang

Zhu

et al . Prognostic significance of combination of preoperative platelet count and neutrophil-lymphocyte ratio (COP-NLR) in patients with non–small cell lung cancer: based on a large cohort study. PLoS One. 2015;10:e0126496.

Ishizuka

Nagata

Takagi

Iwasaki

Kubota

Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer. 2013;109:401-407.

Ishizuka

Oyama

Abe

Kubota

Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients undergoing surgery for gastric cancer. J Surg Oncol. 2014;110:935-941.

10.

Ohsugi

Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull. 2007;30:2001-2006.

11.

Ruscetti

FW.

Hematologic effects of interleukin-1 and interleukin-6. Curr Opin Hematol. 1994;1:210-215.

12.

Nakashima

Matsuoka

Yoshida

et al . Pre-treatment neutrophil to lymphocyte ratio predicts the chemoradiotherapy outcome and survival in patients with oral squamous cell carcinoma: a retrospective study. BMC Cancer. 2016;16:41.

13.

Maihofner

Charalambous

Bhambra

et al . Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis. 2003;24:665-671.

14.

Hugo

Saunders

Ramsay

Thompson

EW.

New insights on COX-2 in chronic inflammation driving breast cancer growth and metastasis. J Mammary Gland Biol Neoplasia. 2015;20:109-119.

15.

Cui

COX-2, MMP-7 expression in oral lichen planus and oral squamous cell carcinoma. Asian Pac J Trop Med. 2013;6:640-643.

16.

Allred

Harvey

Berardo

Clark

GM.

Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168.

17.

Kanda

Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452-458.

18.

Simonsson

Bjorner

Markkula

et al . The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size. Int J Cancer. 2017;140:163-175.

19.

WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2015. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2014.

20.

Coussens

Werb

Inflammation and cancer. Nature. 2002;420:860-867.

21.

Mantovani

Allavena

Sica

Balkwill

Cancer-related inflammation. Nature. 2008;454:436-444.

22.

Nakahira

Sugasawa

Matsumura

et al . Prognostic role of the combination of platelet count and neutrophil-lymphocyte ratio in patients with hypopharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2016;273:3863-3867.

23.

Rassouli

Saliba

Castano

Hier

Zeitouni

AG.

Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinoma. Head Neck. 2015;37:103-110.

24.

Jana

Sarkar

Ganguly

et al . Role of cyclooxygenase 2 (COX-2) in prognosis of breast cancer. Indian J Surg Oncol. 2014;5:59-65.

25.

da Silva

Morand

Alobaid

et al . Epithelial-mesenchymal transition (EMT) markers have prognostic impact in multiple primary oral squamous cell carcinoma. Clin Exp Metastasis. 2015;32:55-63.

26.

Ramsay

Friend

Vizantios

et al . Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB. Cancer Res. 2000;60:1805-1809.

27.

Chen

Raghav

Lieu

et al . Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer. 2015;112:1088-1097.

28.

Perez

Balabram

Rocha

da Silva Souza

Gobbi

Co-expression of p16, Ki67 and COX-2 is associated with basal phenotype in high-grade ductal carcinoma in situ of the breast. J Histochem Cytochem. 2015;63:408-416.

29.

Hao

Zhang

Gao

et al . FOXP3 inhibits NF-kappaB activity and hence COX2 expression in gastric cancer cells. Cell Signal. 2014;26:564-569.

30.

OuYang

et al . COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells. Oncoimmunology. 2015;4:e1044712.

31.

St John

MA.

Inflammatory mediators drive metastasis and drug resistance in head and neck squamous cell carcinoma. Laryngoscope. 2015;125(suppl 3):S1-S11.

32.

Wang

Chow

YC.

Effects of platelet activating factor, butyrate and interleukin-6 on cyclooxygenase-2 expression in human esophageal cancer cells. Scand J Gastroenterol. 2002;37:467-475.

33.

Ock

Nam

Lee

et al . Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer. 2017;20:254-262.